Clinical trial · Interventional
Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia
A Study of Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The main purpose of this study is to find out how well participants with relapsed or refractory ALL respond to treatment with an etoposide- and teniposide-based induction chemotherapy regimen and what the side effects are. Primary Objectives: * To estimate the response rate for patients with refractory or relapsed ALL. * To estimate the survival rate of patients with refractory or relapsed ALL treated with risk-directed therapy.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Lymphoblastic Leukemia | Acute Lymphoblastic Leukemia | ONTOLOGY_EXACT | 0.98 |
| Lymphoma, Lymphoblastic | Lymphoblastic Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (7)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| chemotherapy, intrathecal chemotherapy, steroid therapy | Procedure | — | UNRESOLVED |
| Etoposide, cytarabine, vincristine, dexamethasone | Drug | — | UNRESOLVED |
| Hematopoietic Stem Cell Transplant | Procedure | — | UNRESOLVED |
| L-asparaginase, erwinia asparaginase | Drug | — | UNRESOLVED |
| methotrexate, teniposide, PEG-asparaginase | Drug | — | UNRESOLVED |
| mitoxantrone, cyclophosphamide, mercaptopurine, vinblastine | Drug | — | UNRESOLVED |
| Natural Killer (NK) Cell Transplant | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- Treatment
- description
- Participants receive chemotherapy, intrathecal chemotherapy, steroid therapy, hematopoietic stem cell transplant, and natural killer cell transplant as outlined in the Interventions section, including etoposide, cytarabine, vincristine, dexamethasone, methotrexate, teniposide, PEG-asparaginase, mitoxantrone, cyclophosphamide, mercaptopurine, vinblastine, L-asparaginase, erwinia asparaginase.
- interventionNames
- Drug: Etoposide, cytarabine, vincristine, dexamethasone
- Drug: methotrexate, teniposide, PEG-asparaginase
- Drug: mitoxantrone, cyclophosphamide, mercaptopurine, vinblastine
- Drug: L-asparaginase, erwinia asparaginase
- Procedure: chemotherapy, intrathecal chemotherapy, steroid therapy
- Procedure: Hematopoietic Stem Cell Transplant
- Procedure: Natural Killer (NK) Cell Transplant
Primary outcomes (2)
- measure
- Response Rate
- timeFrame
- End of re-induction Block C (approximately 1 month after the start of therapy)
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Maximum age
- 21 Years
Show eligibility criteria text
Inclusion Criteria * Childhood ALL in first relapse OR in first hematological relapse after an extramedullary relapse, OR not attaining a complete remission with frontline therapies, OR lymphoblastic leukemia in first relapse. * Patients must be 21 years of age or younger * Informed consent explained to and signed by parent/legal guardian. Exclusion Criteria * Life expectancy less than 8 weeks * Patients with mature B cell ALL
References
Publications (0)
Data not yet available